Summary
a2 Milk Company unveiled three new infant formula products at the 2026 China International Import Expo (CIIE): a2 Platinum Premium, a2 Platinum Prestige and an upgraded a2 Platinum. The upgraded a2 Platinum made its global debut at CIIE and was released simultaneously in Australia/New Zealand and China. The product features upgraded DHA, 8x lutein and three human milk oligosaccharide (HMO) related formulations.
HMO has become a core competitive battleground in infant formula: in October 2023, China's National Health Commission approved 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) as food nutritional fortifiers for infant formula; in February 2026, it approved 3'-sialyllactose sodium salt (3'-SL). Danone's Neocate HMO special medical purpose high-energy full-nutrition formula also had its China debut at CIIE. Nestlé said it has more than 30 years of HMO research and holds over 100 HMO-related scientific patents.
Feihe, Yili Jinlingguan and Junlebao have all launched related products. Euromonitor data shows the domestic infant formula market fell from RMB 172.5 billion in 2021 to RMB 141 billion in 2025, a CAGR of -4.9%. Nielsen data shows retail sales in the domestic infant formula market fell 4.4% year-on-year in the 12 months to August 2026.
A market head at a leading foreign infant formula brand said that a few years ago the hot concepts were lactoferrin and DHA, but now HMO is the hottest, and it is a market they cannot afford to lose.
Commentary
China's infant formula market is undergoing structural contraction, with Euromonitor data showing the market falling from RMB 172.5 billion in 2021 to RMB 141 billion in 2025, a compound annual growth rate of -4.9%. Against this backdrop of shrinking volume, HMO (human milk oligosaccharides) has become one of the few differentiated selling points that can support a premium. a2 Milk's global debut of the upgraded a2 Platinum at CIIE, simultaneous with Australia/New Zealand and China, highlights its strategic reliance on the Chinese market.
For NZ SMEs focused on China, the heating up of the HMO track means that formula R&D and clinical endorsement capabilities have become competitive thresholds; smaller brands without patent reserves may be forced into price wars. On the other hand, Chinese regulators have accelerated HMO approvals, approving 2'-FL and LNnT in 2023 and 3'-SL in February 2026, opening a window for New Zealand functional dairy ingredient suppliers with research capabilities. New Zealand has traditional strengths in dairy science and clinical research, but it should be noted that Chinese domestic brands such as Feihe and Yili Jinlingguan have quickly followed suit, and foreign giants Nestlé and Danone have deep patent barriers.
As a New Zealand-listed company, whether a2 Milk's HMO products can revive its share in China will directly affect the order stability of its upstream New Zealand milk suppliers. The infant formula market is declining overall, but high-end functional products are growing against the trend; NZ SMEs should focus on differentiated supply of niche functional ingredients rather than pursuing scale.
Keywords: a2 Milk, HMO, infant formula, CIIE, upgraded a2 Platinum, human milk oligosaccharides, Danone, Nestlé, Feihe, market size
Photo by kewl on Pixabay
Source: Sfccn
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.






